Surgical
Ablation Market Worldwide
Ablation Technologies Worldwide Market, 2009-2019
A worldwide report on the products, technologies, markets and opportunities in ablation
· 488 pages
· 123 Exhibits
· 76 Company Profiles
· June 2010
· Report #A145
Price: $2,250 for print or PDF;
add $200 to receive for both
Add
$1,500 for site license or $2,500 for a global
Order online or via order
form.
This exceptional report is a detailed market and technology assessment and forecast of the
applications, products, technologies and opportunities in the global ablation market for treatment of soft tissues via energy-based modalities, including electrosurgery, radiosurgery, gamma knife, brachytherapy, cryosurgery, fluidjet therapy (hydrotherapy), microwave ablation, radiofrequency ablation, laser, thermal ablation, and ultrasonic ablation.
The report describes alternative energy-based technologies and the nature of their effect on soft tissue, the underlying basis of the technology, the requisite systems for their use (including capital equipment, devices and disposables), and their strengths and weaknesses for specific clinical applications. The
report details current and anticipated target applications and assesses the current and forecast caseload for each energy-based therapeutic considering competition from any and all alternative energy-based or other therapeutics,
with current and worldwide market forecasts (2009-2019) segmented by technology type and specific clinical segment. The
report provides segmentation of the worldwide ablation market by both
ablation technology and region/country: Americas (USA, Canada, Mexico,
Brazil), Europe (Germany, United Kingdom, France, Italy, Spain, BeNeLux),
Asia/Pacific (Japan, China, India, Australia) and Rest of World. The report
details the current and emerging products, technologies and markets for each
energy-based therapy. The report profiles 76 key companies in this industry detailing their current products, current market position and products under development.
Table of Contents
Executive Summary
Section 1:
DISEASE STATES TREATED WITH ENERGY-BASED ABLATIVE TECHNOLOGY
1.1
Overview of Ablation
Technologies for the Treatment of Disease
1.1.1
Electrical
1.1.1.1
Enhancing
Ablation Using Argon Gas
1.1.1.2
Irreversible
Electroporation
1.1.2
Radiation
1.1.2.1
Image-guided
radiotherapy (IGRT)
1.1.2.2
Image-modulated
Radiotherapy (IMRT)
1.1.2.3
Tomotherapy
1.1.2.4
Increased Use of
Hypofractionation, IGRT and IMRT
1.1.2.5
Hyperfractionation May Have its Benefits
1.1.2.6
Radiation and
Concurrent Use of Chemotherapy
1.1.2.7
Brachytherapy
1.1.2.8
Stereotactic
Radiosurgery and SBRT
1.1.2.9
FDA Tightening
Approval Process for Radiation-emitting Devices
1.1.2.10
Nano-radiation
Therapy
1.1.3
Light
1.1.3.1
Lasers and Their
Effects on Tissue
1.1.4
Radiofrequency
1.1.4.1
Temperature
Controlled
1.1.4.2
Fluid Cooled
1.1.4.3
Catheter
Manipulation Systems
1.1.5
Ultrasound
1.1.6
Cryotherapy
1.1.7
Thermal
1.1.8
Microwave
1.1.9
Hydromechanical
1.1.10
Technologies Under
Development
1.1.10.1
Induction Heating
Cancer Therapy (IHCT) Using Magnetic Nanoparticles
1.1.11
Audiosurgery for
Tumors
1.2
Disease States and Applicable
Ablation Technologies
1.2.1
Cancer
1.2.1.1
Breast
1.2.1.1.1
Current and
Emerging Treatment Trends
1.2.1.1.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.1.2
Liver
1.2.1.2.1
Current and Emerging
Treatment Trends
1.2.1.2.2
Applicable Ablation
Technologies: Rationale for Use and Effect on Tissues
1.2.1.3
Lung
1.2.1.3.1
Current and Emerging
Treatment Trends
1.2.1.3.2
Applicable Ablation
Technologies: Rationale for Use and Effect on Tissues
1.2.1.4
Prostate Cancer
1.2.1.4.1
Gleason Grades and
Scores
1.2.1.4.2
Prostate Cancer
Staging
1.2.1.4.3
Current and Emerging
Treatment Trends
1.2.1.4.4
Applicable Ablation
Technologies: Rationale for Use and Effect on Tissues
1.2.1.5
Kidney
1.2.1.5.1
Current and Emerging
Treatment Trends
1.2.1.5.2
Applicable Ablation
Technologies: Rationale for Use and Effect on Tissues
1.2.2
Cardiovascular Disease
1.2.2.1
Angina Pectoris
1.2.2.1.1
Current and Emerging
Treatment Trends
1.2.2.1.2
Applicable Ablation
Technologies: Rationale for Use and Effect on Tissues
1.2.2.2
Atrial Fibrillation and
Atrial Flutter
1.2.2.2.1
Current and Emerging
Treatment Trends
1.2.2.2.2
Applicable Ablation
Technologies: Rationale for Use and Effect on Tissues
1.2.2.3
Ventricular Arrhythmias
1.2.2.3.1
Current and Emerging
Treatment Trends
1.2.2.3.2
Applicable Ablation
Technologies: Rationale for Use and Effect on Tissues
1.2.2.4
Wolf-Parkinson-White
Disease
1.2.2.4.1
Current and Emerging
Treatment Trends
1.2.2.4.2
Applicable Ablation
Technologies: Rationale for Use and Effect on Tissues
1.2.2.5
AVNRT (Atrioventricular
nodal reentry tachycardia)
1.2.2.5.1
Current and Emerging
Treatment Trends
1.2.2.5.2
Applicable Ablation
Technologies: Rationale for Use and Effect on Tissues
1.2.2.6
Critical Limb Ischemia
1.2.2.6.1
Current and Emerging
Treatment Trends
1.2.2.6.2
Applicable Ablation
Technologies: Rationale for Use and Effect on Tissues
1.2.2.7
Critical Ischemic Stroke
1.2.2.7.1
Current and Emerging
Treatment Trends
1.2.2.7.2
Applicable Ablation
Technologies: Rationale for Use and Effect on Tissues
1.2.2.8
Hypertension
1.2.2.8.1
Current and Emerging
Treatment Trends
1.2.2.8.2
Applicable Ablation
Technologies: Rationale for Use and Effect on Tissues
1.2.2.9
Varicose Veins
1.2.2.9.1
Current and Emerging
Treatment Trends
1.2.2.9.2
Applicable Ablation
Technologies: Rationale for Use and Effect on Tissues
1.2.3
Ophthalmology
1.2.3.1
Cataracts
1.2.3.1.1
Current and
Emerging Treatment Trends
1.2.3.1.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.3.2
Disorders of the
Retina
1.2.3.2.1
Current and
Emerging Treatment Trends
1.2.3.2.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.3.3
Vision Correction
1.2.3.3.1
Current and
Emerging Treatment Trends
1.2.3.3.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.3.4
Central Retinal Vein
Occlusion
1.2.3.4.1
Current and
Emerging Treatment Trends
1.2.4
General Surgery
1.2.4.1
Barrett’s Esophagus
1.2.4.1.1
Current and
Emerging Treatment Trends
1.2.4.1.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.4.2
Fecal Incontinence
1.2.4.2.1
Current and
Emerging Treatment Trends
1.2.4.2.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.4.3
Gastroesophageal
Reflux Disease (GERD)
1.2.4.3.1
Current and
Emerging Treatment Trends
1.2.4.3.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.4.4
Tonsillectomy
1.2.4.4.1
Current and
Emerging Treatment Trends
1.2.4.4.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.5
Gynecology
1.2.5.1
Menorrhagia
1.2.5.1.1
Current and
Emerging Treatment Trends
1.2.5.1.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.5.2
Fibroids
1.2.5.2.1
Current and
Emerging Treatment Trends
1.2.5.2.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.5.3
Cervical Dysplasia
and Cancer
1.2.5.3.1
Current and
Emerging Treatment Trends
1.2.5.3.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.6
Pain Management
1.2.6.1
Current and Emerging
Treatment Trends
1.2.6.2
Applicable Ablation
Technologies: Rationale for Use and Effect on Tissues
1.2.7
Urology
1.2.7.1
Kidney Stones
1.2.7.1.1
Current and
Emerging Treatment Trends
1.2.7.1.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.7.2
Benign Prostatic
Hypertrophy (BPH)
1.2.7.2.1
Current and
Emerging Treatment Trends
1.2.7.2.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.8
Orthopedics
1.2.8.1
Joint Instability
(Conducting Capsular Shrinkage)
1.2.8.1.1
Current and
Emerging Treatment Trends
1.2.8.1.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.8.2
Chondroplasty
1.2.8.2.1
Current and
Emerging Treatment Trends
1.2.8.2.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.8.3
Discogenic Back Pain
1.2.8.3.1
Current and
Emerging Treatment Trends
1.2.8.3.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.9
Aesthetic Treatments
1.2.9.1
Body Contouring
1.2.9.1.1
Current and
Emerging Treatment Trends
1.2.9.1.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.9.2
Laser Hair Removal
1.2.9.2.1
Current and
Emerging Treatment Trends
1.2.9.2.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.9.3
Laser Tattoo Removal
1.2.9.3.1
Current and
Emerging Treatment Trends
1.2.9.3.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.9.4
Port-wine Stains
1.2.9.4.1
Current and
Emerging Treatment Trends
1.2.9.4.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.9.5
Psoriasis
1.2.9.5.1
Current and
Emerging Treatment Trends
1.2.9.5.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.9.6
Scar Reduction and
Removal
1.2.9.6.1
Current and
Emerging Treatment Trends
1.2.9.6.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.10
Other Treatments
1.2.10.1
Severe Asthma
1.2.10.1.1
Current and
Emerging Treatment Trends
1.2.10.1.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
1.2.10.2
Unresectable Liver
Tumors
1.2.10.2.1
Current and
Emerging Treatment Trends
1.2.10.2.2
Applicable
Ablation Technologies: Rationale for Use and Effect on
Tissues
Section 2:
Products and Technologies
Comprehensive product listing and selected recent developments discussed
2.1
Electrical
2.2
Radiation
2.2.1
Brachytherapy
2.2.2
High-Dose-Rate (HDR)
Brachytherapy
2.2.3
Pulsed-Dose-Rate (PDR)
Brachytherapy
2.2.4
Permanent Seed Prostate
Brachytherapy (LDR)
2.2.5
Stereotactic Radiosurgery
(SRS) and Stereotactic Radiotherapy (SRT)
2.2.6
Stereotactic Body
Radiation Therapy (SBRT)
2.2.7
Proton Beam Therapy
2.3
Light/Laser
2.4
Radiofrequency
2.4.1
RF Ablation for Atrial
Fibrillation
2.4.2
RF Electrosurgical
Devices
2.5
Ultrasound
2.6
Cryotherapy
2.7
Thermal
2.8
Microwave
2.9
Hydromechanical
Section 3:
Market Assessment
3.1
World Market Overview
3.2
Market Segmentation by
Product Type
3.2.1
Electrical
3.2.2
Radiation
3.2.3
Light
3.2.4
Radiofrequency
3.2.5
Ultrasound
3.2.6
Cryotherapy
3.2.7
Thermal
3.2.8
Microwave
3.2.9
Hydromechanical
3.3
Market Trends
3.3.1
Market Drivers
3.3.1.1
Aging populations
3.3.1.2
Cardiac Arrhythmias
3.3.1.3
Cancer
3.3.1.4
Healthcare Economics
3.3.2
Market Restraints
3.3.2.1
Recession
3.3.2.2
US Healthcare Reforms
3.3.2.3
Procedure Time
3.3.2.4
Cost of Capital
Expenditure
3.4
Leading Companies in Global
Market
3.5
Major National Markets
3.5.1
Americas
3.5.1.1
U.S.A.
3.5.1.2
Canada
3.5.1.3
Mexico
3.5.1.4
Brazil
3.5.2
European Union
3.5.2.1
United Kingdom
3.5.2.2
Germany
3.5.2.3
France
3.5.2.4
Spain
3.5.2.5
Italy
3.5.2.6
BeNeLux
3.5.3
Asia/Pacific
3.5.3.1
Japan
3.5.3.2
China
3.5.3.3
India
3.5.3.4
Australia
3.5.4
Rest of World
Section 4:
Company Profiles
(Select companies profiled; note that not
all companies covered in the report are profiled.)
4.1
Accuray
4.1.1
CyberKnife Robotic
Radiosurgery System
4.1.2
CyberKnife VSI System
4.1.3
CyberKnife for
Unresectable Renal Tumors
4.1.4
International Randomized
Study to Compare CyberKnife Stereotactic Radiotherapy With Surgical
Resection In Stage I Non-small Cell Lung Cancer (STARS)
4.1.5
CyberKnife Radiosurgery
For Low & Intermediate Risk Prostate Cancer: Emulating HDR
Brachytherapy Dosimetry
4.1.6
CyberKnife Radiosurgical
Treatment of Inoperable Early Stage Non-Small Cell Cancer
4.2
Alcon Laboratories
4.2.1
Infiniti Vision System
4.2.2
Constellation Vision
System
4.2.3
Purepoint Laser
4.2.4
Allegretto Wave Eye-Q
Excimer Laser System
4.2.5
Bid from Novartis to
Acquire Alcon
4.3
American Medical Systems
4.3.1
TherMatrx Office Thermo
Therapy
4.3.2
GreenLight Laser Therapy
4.4
AngioDynamics
4.4.1
StarBurst XL RFA device
4.4.2
The Habib 4X bipolar
resection device
4.4.3
NanoKnife IRE System
4.4.4
VenaCure EVLT
4.4.5
A Prospective,
Multi-Center, Clinical Trial Using Irreversible Electroporation
(IRE) for the Treatment of Early-Stage Hepatocellular Carcinoma (HCC)
4.5
Ardian, Inc.
4.5.1
Symplicity I Trial
4.5.2
Symplicity HTN-2 Trial
4.6
ArthroCare Corporation
4.6.1
Coblation-Tonsillotomy vs
Electrocautery-Tonsillectomy for the Treatment of Obstructive Sleep
Apnea (OSA) in Children
4.7
Asthmatx, Inc.
4.7.1
Asthma Intervention
Research 2 (AIR2) Trial
4.8
AtriCure
4.8.1
The AtriCure Synergy
Bipolar System
4.8.2
Bipolar Radiofrequency
Ablation of Permanent Atrial Fibrillation (ABLATE)
4.8.3
RESTORE SR IIB
4.9
ATS Medical
4.9.1
ATS CryoMaze
4.10
Bard Electrophysiology
4.10.1
MAGELLAN
4.11
Barrx Medical
4.11.1
Micro-Layer Ablation of
Barrett's Metaplasia- A Two-Phase, Multi-Center Trial - Extension of
Follow-up to 5 Years (AIM)
4.11.2
Endoscopic RF Ablation
for Barrett’s Esophagus: Five-Year Durability Outcomes from a
Prospective Multi-Center Trial
4.12
Bausch + Lomb
4.12.1
Stellaris Vision
Enhancement System
4.12.2
Millennium Microsurgical
System
4.13
Baylis Medical
4.13.1
TransDiscal System
4.14
Biosense Webster
4.14.1
Irrigated Tip Catheter
product lines
4.14.2
NaviStar ThermoCool
Catheter for the Treatment of AF—TX Clinical Trial
4.14.3
CLARITY Clinical Study
4.14.4
Study of a New Catheter
Using Force Sensing Capabilities for the Treatment of AF and
Ventricular Tachycardia (EZCF-125)
4.14.5
NaviStar ThermoCool
Catheter for the Radiofrequency Ablation of Drug Refractory
Recurrent Symptomatic Paroxysmal AF Clinical Trial
4.15
Biotronik
4.15.1
AlCath Flux/AlCath Flux
Gold Ablation Catheters
4.16
Boston Scientific
4.16.1
VersaPulse PowerSuite 100
Watt Holmium laser
4.16.2
Prolieve Thermodilatation
System
4.16.3
Blazer II X Temperature
Ablation Catheter
4.16.4
RF 3000 Radiofrequency
Ablation System
4.16.5
iLab Ultrasound Imaging
System with Ultra ICE Catheter
4.16.6
Prolieve Post-Marketing
Study Treatment of Benign Prostatic Hyperplasia (BPH)
4.16.7
A Prospective Randomized
Study Comparing Radiofrequency Energy With Cryoenergy (CRYO-RF)
4.17
Bovie Medical
4.17.1
The Aaron line of
electrosurgical products
4.17.2
The Bovie line of
electrosurgery generators
4.17.3
MEG Endoscopic
Instruments
4.18
BSD Medical
4.18.1
Phase III Clinical Trial
of the BSD-2000 Hyperthermia System
4.18.2
Phase II MicroThermX®
Microwave Ablation System (MTX-180)
4.18.3
BSD 500 Hyperthermia
System
4.18.4
BSD-2000
4.19
Cardima
4.19.1
Cardima Surgical Ablation
System
4.19.2
Cardima EP Ablation
System
4.19.3
Cardima Revelation T-Flex
Ablation device
4.20
CardioFocus
4.20.1
Clinical Study of the
CardioFocus Endoscopic Ablation System - Adaptive Contact (CFEAS-
AC) for the Treatment of Symptomatic Atrial Fibrillation
4.21
CardioGenesis
4.22
Celon AG
4.22.1
Surgery/Radiology
4.22.2
Phlebology
4.23
Chongqing Haifu (HIFU)
Technology Co. Ltd.
4.24
Cook Group
4.24.1
LMA StoneBreaker
Pneumatic Lithotripter
4.24.2
Odyssey 30 Holmium Laser
System
4.24.3
The StoneBreaker Trial
4.25
ConMed
4.25.1
Beamer System CE600
4.26
Covidien
4.26.1
Electrosurgery
4.26.2
VNUS Medical Technologies
4.26.2.1
ClosureFAST System
4.26.2.2
LigaSure RF Ablation
device
4.27
CryoMedix
4.28
CSA Medical
4.28.1
Study of CryoSpray
Ablation to Determine Treatment Effect, Depth of Injury, and Side
Effects in the Esophagus. (CSA Depth 3)
4.29
Cynosure
4.30
Dornier MedTech
4.30.1
Compact Delta II and
Delta II UIMS
4.30.2
Dornier Lithotripter S II
4.30.3
Dornier Medilas D
MultiBeam
4.30.4
Dornier Medilas H 20
4.31
EDAP TMS S.A.
4.31.1
Ablatherm HIFU
4.31.2
Sonolith i-move
4.31.3
ENLIGHT Clinical Trial
4.32
Elekta
4.32.1
Elekta Axesse
4.32.2
Elekta Infinity
4.32.3
Elekta Synergy S
4.32.4
Leksell Gamma Knife®
Perfexion Stereotactic radiosurgery system
4.33
EndoPhotoniX
4.33.1
Solar & Atrilaze Atrial
Fibrillation Trial (SAAF-T)
4.34
Endosense
4.34.1
TOCCATA Clinical Trial
4.34.2
EFFICAS I
4.35
Erbe Elektromedizin GmbH
4.36
Ethicon Endo-Surgery
4.37
Galil Medical
4.38
Gynesonics
4.39
Halt Medical
4.39.1
Laparoscopic
Radiofrequency Ablation of Symptomatic Uterine Fibroids (Halt Lap
RFA)
4.40
Hansen Medical
4.41
HealthTronics, Inc.
4.42
Hologic, Inc.
4.42.1
NovaSure Endometrial
Ablation system
4.42.2
Digital mammography and
breast biopsy
4.43
IBt-Bebig, SA
4.44
InSightec
4.44.1
ExAblate (Magnetic
Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic
Bone Tumors for the Palliation of Pain
4.44.2
Study Comparing the
Safety and Effectiveness of Magnetic Resonance Guided Focused
Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment
of Metastatic Bone Tumors and Multiple Myeloma
4.45
Integra LifeSciences
4.46
Medtronic
4.46.1
Cardiac Rhythm Disease
Management (CRDM)
4.46.2
Spinal and Biologics
4.46.3
CardioVascular
4.46.4
Neuromodulation
4.46.5
Diabetes
4.46.6
Surgical Technologies
4.46.7
AF Solutions Franchise
4.46.8
Arctic Front Cardiac
CryoAblation Catheter
4.46.9
Cardiac CryoAblation
System
4.46.10
The STOP AF Clinical
Trial
4.46.11
The TTOP AF Clinical
Trial
4.46.12
The CURE-AF/Perst
Clinical Trial
4.47
Mederi Therapeutics
4.47.1
Secca Procedure for fecal
incontinence
4.47.2
Stretta Procedure for
GERD
4.48
MedWaves
4.49
Mirabilis Medica
4.50
Misonix
4.50.1
Sonablate 500
4.50.2
SonaStar Ultrasonic
Surgical Aspirator
4.50.3
Bone Scalpel Ultrasonic
Bone Cutter
4.51
nContact Surgical
4.51.1
Numeris Coagulation
System with VisiTrax
4.51.2
Numeris-AF Tethered
Coagulation System for Treatment of Longstanding Persistent Atrial
Fibrillation (AF)
4.51.3
Safety and Efficacy Study
of The Combined Ablation Procedure To Treat Longstanding Persistent
Atrial Fibrillation (CAPstopsLSPAF)
4.51.4
Safety and Efficacy Study
of the Combined Ablation Procedure to Treat Paroxysmal Atrial
Fibrillation (CAP STOPS AF)
4.52
NeuWave Medical
4.52.1
Certus 140
4.53
Novian Health
4.53.1
Novilase
4.53.2
American Breast Laser
Ablation Therapy Evaluation (ABLATE)
4.54
NuVue Therapeutics
4.55
Olympus Medical
4.55.1
UES-40 SurgMaster
Electrosurgical Unit
4.55.2
SonoSurg Ultrasonic
Surgical System
4.56
PhotoMedex
4.57
PhotoThera
4.58
RFA Medical
4.58.1
InCircle RF Ablation
4.59
Sanarus Technologies LLC
4.59.1
Cassi II Core Biopsy
Device
4.59.2
ImarC Tissue Marker
System
4.59.3
Visica 2 Treatment System
4.59.4
Z1072 Clinical Trial
4.60
SenoRx
4.60.1
Contura Multi-Lumen
Balloon (MLB)
4.60.2
Multi-Site, Prospective,
Non-Randomized Study of the Contura Multi-Lumen Balloon (MLB)
Catheter to Deliver Accelerated Partial Breast Irradiation: Analysis
of Dosimetry, Local Tumor Control, Cosmetic Outcome, and Toxicity
4.61
Siemens Healthcare
4.61.1
Siemens to put greater
focus on healthcare businesses
4.61.2
Primatom System (IGRT)
4.61.3
Oncor
4.62
Smith & Nephew
4.62.1
Versajet Hydrosurgery
System
4.62.2
Dyonics RF System
4.63
Solta Medical
4.63.1
Fraxel re:pair
4.64
Spectrasonics
4.65
St. Jude Medical
4.65.1
Atrial Fibrillation
4.65.2
CABANA Clinical Trial
4.65.3
IRASE AF Clinical Trial
4.65.4
Modified
stepwise Ablation Guided by low dose Ibutilide
Use in Chronic Atrial Fibrillation Trial
(MAGIC-AF)
4.65.5
AFMAZE-CABG Clinical
Trial
4.65.6
Clinical Evaluation of
Therapy Cool Path Duo Cardiac Ablation System for the Treatment of
Ischemic Ventricular Tachycardia (VT) (Ablate-VT)
4.66
Starion
Instruments
4.67
Stereotaxis
4.67.1
Stereotaxis
Magnetic Navigation System
4.68
Theragenics
4.69
TomoTherapy
4.69.1
Hi-Art Treatment System
4.70
Uptake Medical
4.70.1
Bronchoscopic Thermal
Vapor Ablation (BTVA) for Lung Volume Reduction
4.71
Urologix
4.71.1
Targis System
4.72
US HIFU, LLC
4.72.1
Sonablate 500
4.72.2
Primary Prostate Cancer Clinical Trial
4.72.3
Recurrent HIFU Clinical
Trial
4.73
Varian Medical Systems
4.73.1
Novalis Tx radiosurgery
platform
4.73.2
RapidArc
4.73.3
Dynamic Targeting
Image-Guided Radiation Therapy (IGRT)
4.73.4
SmartBeam IMRT
4.73.5
Dynamic Adaptive
Radiotherapy (DART)
4.73.6
Acuity™ BrachyTherapy
Suite™ integrated IGBT solution
4.73.7
Varian Proton Therapy
System
4.74
Visualase
4.74.1
Magnetic Resonance
Temperature Imaging & Imaging-Guided Laser Induced Thermal Therapy
for Treatment of Metastatic Brain Tumors
4.75
Xoft
4.75.1
Electronic Xoft
Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For
Treatment of Early Stage Breast Cancer (EXIBT)
4.75.2
Xoft
Electronic Brachytherapy Clinical Protocol for the Primary Treatment
of Non-Melanoma Skin Cancer
4.76
Zeltiq Aesthetics
4.76.1
Non-Invasive Reduction of
Abdominal Fat (JUNO)
Section 5:
Key Clinical Trials
5.1
Electrical
5.1.1
AngioDynamics
5.1.1.1
A Prospective,
Multi-Center, Clinical Trial Using Irreversible Electroporation
(IRE) for the Treatment of Early-Stage Hepatocellular Carcinoma
(HCC)
5.1.2
ArthroCare
5.1.2.1
Coblation-Tonsillotomy vs Electrocautery-Tonsillectomy for the
Treatment of Obstructive Sleep Apnea (OSA) in Children
5.2
Radiation
5.2.1
Accuray
5.2.1.1
CyberKnife for
Unresectable Renal Tumors
5.2.1.2
CyberKnife for
Unresectable Renal Tumors
5.2.1.3
International
Randomized Study to Compare CyberKnife Stereotactic Radiotherapy
With Surgical Resection In Stage I Non-small Cell Lung Cancer
(STARS)
5.2.1.4
CyberKnife
Radiosurgery For Low & Intermediate Risk Prostate Cancer:
Emulating HDR Brachytherapy Dosimetry
5.2.1.5
CyberKnife
Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell
Cancer
5.2.2
SenoRx
5.2.2.1
Multi-Site,
Prospective, Non-Randomized Study of the Contura Multi-Lumen
Balloon (MLB) Catheter to Deliver Accelerated Partial Breast
Irradiation: Analysis of Dosimetry, Local Tumor Control,
Cosmetic Outcome, and Toxicity
5.2.3
Xoft
5.2.3.1
Electronic Xoft
Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT)
For Treatment of Early Stage Breast Cancer (EXIBT)
5.2.3.2
Xoft Electronic
Brachytherapy Clinical Protocol for the Primary Treatment of
Non-Melanoma Skin Cancer
5.3
Light
5.3.1
CardioFocus
5.3.1.1
Endoscopic Ablation
System—Adaptive Contact (EAS-AC) for the Treatment of
Symptomatic AF
5.3.2
EndoPhotoniX
5.3.2.1
Solar & Atrilaze
Atrial Fibrillation Trial (SAAF-T)
5.3.3
Novian Health
5.3.3.1
American Breast Laser
Ablation Therapy Evaluation (ABLATE)
5.3.4
Visualase
5.3.4.1
Magnetic Resonance
Temperature Imaging & Imaging-Guided Laser Induced Thermal
Therapy for Treatment of Metastatic Brain Tumors
5.4
Radiofrequency
5.4.1
Ardian, Inc.
5.4.1.1
Symplicity I Trial
5.4.1.2
Symplicity HTN-2
Trial
5.4.2
Asthmatx
5.4.2.1
Asthma Intervention
Research 2 (AIR2) Trial
5.4.3
AtriCure
5.4.3.1
Bipolar
Radiofrequency Ablation of Permanent Atrial Fibrillation
(ABLATE)
5.4.3.2
RESTORE-SR IIB
5.4.4
Bard EP
5.4.4.1
MAGELLAN
5.4.5
Barrx Medical
5.4.5.1
Micro-Layer Ablation
of Barrett's Metaplasia- A Two-Phase, Multi-Center Trial -
Extension of Follow-up to 5 Years (AIM)
5.4.5.2
Endoscopic RF
Ablation for Barrett’s Esophagus: Five-Year Durability Outcomes
from a Prospective Multi-Center Trial
5.4.6
Biosense
Webster
5.4.6.1
NaviStar
ThermoCool Catheter for the Treatment of AF—TX Clinical Trial
5.4.6.2
CLARITY
5.4.6.3
Study of a New
Catheter Using Force Sensing Capabilities for the Treatment of
AF and Ventricular Tachycardia (EZCF-125)
5.4.6.4
NaviStar
ThermoCool Catheter for the Radiofrequency Ablation of Drug
Refractory Recurrent Symptomatic Paroxysmal AF Clinical Trial
5.4.7
BSD Medical
5.4.7.1
BSD-2000 RF
Hyperthermia with Chemotherapy for Pancreatic Cancer
5.4.8
Endosense
5.4.8.1
EFFICAS I
5.4.8.2
TOCCATA Clinical
Trial
5.4.9
Halt Medical
5.4.9.1
Laparoscopic
Radiofrequency Ablation of Symptomatic Uterine Fibroids (Halt
Lap RFA)
5.4.10
Medtronic
5.4.10.1
The CURE-AF/Perst
Clinical Trial
5.4.10.2
The TTOP AF Clinical
Trial
5.4.11
nContact Surgical
5.4.11.1
Numeris-AF Tethered
Coagulation System for Treatment of Longstanding Persistent
Atrial Fibrillation (AF)
5.4.11.2
Safety and Efficacy
Study of The Combined Ablation Procedure To Treat Longstanding
Persistent Atrial Fibrillation (CAPstopsLSPAF)
5.4.11.3
Safety and Efficacy
Study of the Combined Ablation Procedure to Treat Paroxysmal
Atrial Fibrillation (CAP STOPS AF)
5.4.12
St. Jude Medical
5.4.12.1
CABANA Clinical Trial
5.4.12.2
IRASE AF Clinical
Trial
5.4.12.3
Modified stepwise
Ablation Guided by low dose Ibutilide Use in Chronic Atrial Fibrillation Trial
(MAGIC-AF)
5.4.12.4
Clinical Evaluation
of Therapy Cool Path Duo Cardiac Ablation System for the
Treatment of Ischemic Ventricular Tachycardia (VT) (Ablate-VT)
5.5
Ultrasound
5.5.1
EDAP TMS
5.5.1.1
Enlight Clinical
Trial
5.5.2
InSightec
5.5.2.1
ExAblate (Magnetic
Resonance-guided Focused Ultrasound Surgery) Treatment of
Metastatic Bone Tumors for the Palliation of Pain
5.5.3
St. Jude Medical
5.5.3.1
AFMAZE-CABG Clinical
Trial
5.5.4
US HIFU
5.5.4.1
Clinical Study of the
Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer (SetPace)
5.5.4.2
A Multicenter
Clinical Study of the Sonablate 500 for the Treatment of Locally
Recurrent Prostate Cancer With HIFU (STAR)
5.6
Cryotherapy
5.6.1
Boston Scientific
5.6.1.1
A Prospective
Randomized Study Comparing Radiofrequency Energy with Cryoenergy
(CRYO-RF)
5.6.2
CSA Medical
5.6.2.1
Study of CryoSpray
Ablation to Determine Treatment Effect, Depth of Injury, and
Side Effects in the Esophagus. (CSA Depth 3)
5.6.3
Medtronic
5.6.3.1
The STOP AF Clinical
Trial
5.6.4
Sanarus Medical
Technologies LLC
5.6.4.1
Z1072 Clinical Trial
5.6.5
Zeltiq Aesthetics
5.6.5.1
Non-Invasive
Reduction of Abdominal Fat (JUNO)
5.7
Thermal
5.7.1
Ethicon
5.7.1.1
ThermaChoice III
Under Local Sedation in the Office Setting
5.7.2
Uptake Medical
5.7.2.1
Bronchoscopic Thermal
Vapor Ablation (BTVA) for Lung Volume Reduction (VAPOR)
5.8
Microwave
5.8.1
Boston Scientific
5.8.1.1
Prolieve
Post-Marketing Study Treatment of Benign Prostatic Hyperplasia (BPH)
5.8.2
MedWaves
5.8.2.1
Microwave Ablation of
Resectable Liver Tumors
5.9
Hydromechanical
5.9.1
Cook Medical
5.9.1.1
The StoneBreaker
Trial
5.9.2
Smith & Nephew
5.9.2.1
Trial of Versajet
Compared With Conventional Treatment in Acute and Chronic Wounds
Appendix I:
COMPANY DIRECTORY
Appendix II: RELEVANT ORGANIZATIONS
Appendix III: ABBREVIATIONS AND TERMS USED IN THIS REPORT
List of
Exhibits
Exhibit ES-1: Global Energy-based Ablation Devices
Markets, 2009-2019
Exhibit ES-2: Percent USD Shares of Global Market by
Modality, Energy-based Ablation Devices, 2009
Exhibit ES-3: Growth of the Global Energy-based Ablation
Device Market, 2009-2019
Exhibit ES-4: Global Incidence and Prevalence (where
known) for Conditions Treated with Energy-Based Ablation Devices
Exhibit ES-5: Share of Energy-based Market by Clinical
Market Segment, 2010
Exhibit ES-6: Global Market Leaders, Energy-based
Ablation Devices, 2009
Exhibit ES-7: Leading Companies in Energy-based Ablation
Device Market, 2010
Exhibit 1-1: Global Number of Selected Surgical
Procedures, Electrical Ablation, 2009
Exhibit 1-2: Share of Energy-based Market by Clinical
Market Segment, 2010
Exhibit 1-3: World Age-Standardized Cancer Incidence per
100,000 Population (All Ages), by Cancer Type
Exhibit 1-4: Global Incidence and Prevalence for
Conditions Treated with Energy-Based Ablation Devices
Exhibit 1-5: Staging of Prostate Cancer
Exhibit 1-6: Treatment Options for Clinically Localized
Prostate Cancer
Exhibit 1-7: Estimated Total Cardiac Ablation
Procedures, 2009 and 2019
Exhibit 1-8: Actual and Estimated RF Ablation
Procedures, 2009-2010: US, EU, Japan
Exhibit 2-1: Energy-based Ablation Device Companies and
Products
Exhibit 2-2: Electrical Ablation Device Companies,
Products & Applications
Exhibit 2-3: Radiation Ablation Device Companies,
Products & Applications
Exhibit 2-4: States Not Covered by Medicare for CyberKnife Treatment of Prostate Cancer
Exhibit 2-5: Light-based Ablation Device Companies,
Products & Applications
Exhibit 2-6: Radiofrequency-based Ablation Device
Companies, Products & Applications
Exhibit 2-7: Ultrasound-based Ablation Device Companies,
Products & Applications
Exhibit 2-8: Cryotherapy Ablation Device Companies,
Products & Applications
Exhibit 2-9: Thermal Ablation Device Companies, Products
& Applications
Exhibit 2-10: Microwave Ablation Device Companies,
Products & Applications
Exhibit 2-11: Hydromechanical Ablation Device Companies,
Products & Applications
Exhibit 3-1: Percent USD Shares of Global Market by
Modality, Energy-based Ablation Devices, 2009
Exhibit 3-2: 2009 Energy-based Ablation Modalities
Global Market Size & CAGR (2010-2019)
Exhibit 3-3: Energy-Based Ablation Devices Global Market
Sizes, 2009-2019 (USD millions)
Exhibit 3-4: Global Energy-based Ablation Device Market,
by Product Type, 2009-2019
Exhibit 3-5: Global Electrical Ablation Market,
2009-2019
Exhibit 3-6: Market Shares of Leading Competitors,
Electrical, 2009
Exhibit 3-7: Electrical Ablation Device Market, % per
Region, 2009
Exhibit 3-8: Americas Market for Electrical Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-9: EU Market for Electrical Ablation Devices,
2009-2019 (USD millions)
Exhibit 3-10: Asia-Pacific Market for Electrical
Ablation Devices, 2009-2019 (USD millions)
Exhibit 3-11: Rest of World Market for Electrical
Ablation Devices, 2009-2019 (USD millions)
Exhibit 3-12: Global Radiation Ablation Market,
2009-2019
Exhibit 3-13: Market Shares of Leading Competitors,
Radiation Ablation Devices, 2009
Exhibit 3-14: Radiation Ablation Device Market, % per
Region, 2009
Exhibit 3-15: Americas Market for Radiation Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-16: EU Market for Radiation Ablation Devices,
2009-2019 (USD millions)
Exhibit 3-17: Asia-Pacific Market for Radiation Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-18: Rest of World Market for Radiation
Ablation Devices, 2009-2019 (USD millions)
Exhibit 3-19: Global Light-based Ablation Market,
2009-2019
Exhibit 3-20: Light-based Ablation Device Market, % per
Region, 2009
Exhibit 3-21: Americas Market for Light-based Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-22: EU Market for Light-based Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-23: Asia-Pacific Market for Light-based
Ablation Devices, 2009-2019 (USD millions)
Exhibit 3-24: Rest of World Market for Light-based
Ablation Devices, 2009-2019 (USD millions)
Exhibit 3-25: Global Radiofrequency Ablation Market,
2009-2019
Exhibit 3-26: Market Shares of Leading Competitors,
Radiofrequency Ablation Devices, 2009
Exhibit 3-27: Radiofrequency Ablation Device Market, %
per Region, 2009
Exhibit 3-28: Americas Market for Radiofrequency
Ablation Devices, 2009-2019 (USD millions)
Exhibit 3-29: EU Market for Radiofrequency Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-30: Asia-Pacific Market for Radiofrequency
Ablation Devices, 2009-2019 (USD millions)
Exhibit 3-31: Rest of World Market for Radiofrequency
Ablation Devices, 2009-2019 (USD millions)
Exhibit 3-32: Global Market for Ultrasound Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-33: Market Shares of Leading Competitors,
Ultrasound Ablation Devices, 2009
Exhibit 3-34: Ultrasound Ablation Device Market, % per
Region, 2009
Exhibit 3-35: Americas Market for Ultrasound Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-36: EU Market for Ultrasound Ablation Devices,
2009-2019 (USD millions)
Exhibit 3-37: Asia-Pacific Market for Ultrasound
Ablation Devices, 2009-2019 (USD millions)
Exhibit 3-38: Rest of World Market for Ultrasound
Ablation Devices, 2009-2019 (USD millions)
Exhibit 3-39: Global Market for Cryotherapy Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-40: Market Shares of Leading Competitors,
Cryotherapy Ablation Devices, 2009
Exhibit 3-41: Americas Market for Cryotherapy Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-42: EU Market for Cryotherapy Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-43: Asia-Pacific Market for Cryotherapy
Ablation Devices, 2009-2019 (USD millions)
Exhibit 3-44: Rest of World Market for Cryotherapy
Ablation Devices, 2009-2019 (USD millions)
Exhibit 3-45: Global Market for Thermal Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-46: Market Shares of Leading Competitors,
Thermal Ablation Devices, 2009
Exhibit 3-47: Thermal Ablation Device Market, % per
Region, 2009
Exhibit 3-48: Americas Market for Thermal Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-49: EU Market for Thermal Ablation Devices,
2009-2019 (USD millions)
Exhibit 3-50: Asia-Pacific Market for Thermal Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-51: Rest of World Market for Thermal Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-52: Global Market for Microwave Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-53: Market Shares of Leading Competitors,
Microwave Ablation Devices, 2009
Exhibit 3-54: Microwave Ablation Device Market, % per
Region, 2009
Exhibit 3-55: Americas Market for Microwave Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-56: EU Market for Microwave Ablation Devices,
2009-2019 (USD millions)
Exhibit 3-57: Asia-Pacific Market for Microwave Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-58: Rest of World Market for Microwave
Ablation Devices, 2009-2019 (USD millions)
Exhibit 3-59: Global Market for Hydromechanical Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-60: Market Shares of Leading Competitors,
Hydromechanical Ablation Devices, 2009
Exhibit 3-61: Americas Market for Hydromechanical
Ablation Devices, 2009-2019 (USD millions)
Exhibit 3-62: EU Market for Hydromechanical Ablation
Devices, 2009-2019 (USD millions)
Exhibit 3-63: Asia-Pacific Market for Hydromechanical
Ablation Devices, 2009-2019 (USD millions)
Exhibit 3-64: Rest of World Market for Hydromechanical
Ablation Devices, 2009-2019 (USD millions)
Exhibit 3-65: Ablation Product Estimated Revenues in Cancer Applications, by Modality, 2010
Exhibit 3-66: Leading Companies in the Global
Energy-based Ablation Market, 2009
Exhibit 3-67: Global Market Leaders, Energy-based
Ablation Devices, 2009
Exhibit 3-68: Energy-based Ablation Device Markets, USA,
2009-2019
Exhibit 3-69: Energy-based Ablation Device Markets,
Canada, 2009-2019
Exhibit 3-70: Energy-based Ablation Device Markets,
Mexico, 2009-2019
Exhibit 3-71: Energy-based Ablation Device Markets,
Brazil, 2009-2019
Exhibit 3-72: Energy-based Ablation Device Markets, UK,
2009-2019
Exhibit 3-73: Energy-based Ablation Device Markets,
Germany, 2009-2019
Exhibit 3-74: Energy-based Ablation Device Markets,
France, 2009-2019
Exhibit 3-75: Energy-based Ablation Device Markets,
Spain, 2009-2019
Exhibit 3-76: Energy-based Ablation Device Markets,
Italy, 2009-2019
Exhibit 3-77: Energy-based Ablation Device Markets, BeNeLux, 2009-2019
Exhibit 3-78: Energy-based Ablation Device Markets,
Japan, 2009-2019
Exhibit 3-79: Energy-based Ablation Device Markets,
China, 2009-2019
Exhibit 3-80: Energy-based Ablation Device Markets,
India, 2009-2019
Exhibit 3-81: Energy-based Ablation Device Markets,
Australia, 2009-2019
Exhibit 3-82: Energy-based Ablation Device Markets, ROW,
2009-2019
Exhibit 4-1: Accuray, Inc. Financial Results for Year
Ending June 27, 2009
Exhibit 4-2: AngioDynamics Consolidated Statement of
Operations, July 2009
Exhibit 4-3: ArthroCare Financial Results
Exhibit 4-4: ATS Medical, Inc., Condensed Consolidated
Statements of Operations
Exhibit 4-5: Boston Scientific Corporation Financials,
2007-2009
Exhibit 4-6: Covidien, Fiscal Years 2007-2009
Exhibit 4-7: Elekta Income Statements, 2006-2009
Exhibit 4-8: IBt-Bebig Financial Results, 2009
Exhibit 4-9: Medtronic’s Company & Product Line
Acquisitions, 2008-2010
Exhibit 4-10: Medtronic Revenue by Operating Segment,
2008-2010
Exhibit 4-11: Medtronic Annual Income Statements,
2006-2010
Exhibit 4-12: SenoRx Financials, 2008-2009
Exhibit 4-13: Summary of St. Jude Medical’s Products for
Atrial Fibrillation
Exhibit 4-14: Five-Year Summary Financial Data, St. Jude
Medical
Exhibit 4-15: Theragenics 2009 Annual Report: Net Income
Statement
Exhibit 4-16: Varian Medical Systems Financials,
2008-2009
Ablation Technologies Worldwide Market: Products, Technologies
Markets, Companies and Opportunities, 2009-2019.
Report #A145. Published June 2010
Price: $2,250 for print or PDF;
add $200 to receive for both
Add
$1,500 for site license or $2,500 for a global
Order
online or via
order form.
Methodology.
MedMarket Diligence Reports are produced through primary
and secondary research. Data is gathered from published sources on products
and technologies on the market and under development. Clinicians and industry
representatives are interviewed for their knowledge and insights on product
development, market development, clinical practice and trends associated with
the evolving use of technologies. Secondary data is used to corroborate and
support assessments and projections. Reports are written and researched
by industry insiders, whose familiarity with the companies, industry dynamics
and other marketplace specifics facilitate the research process and ensure high
quality and thorough reports. |
Or contact: Patrick Driscoll, (949) 859-3401 or patrick <at>
mediligence <dot> com.
Refund Policy:
MedMarket Diligence print publications may be returned within 30 calendar days of purchase and must be in re-saleable condition for a refund to be issued. No refunds will be provided for digital products such as PDFs; customers are therefore advised to carefully evaluate information (website samples, descriptions, and information otherwise provided by MedMarket Diligence) on publications prior to purchase.
Copyright © 2011 MedMarket Diligence, LLC. All rights
reserved.
About Patrick Driscoll
Revised: 04/06/11
See free press
releases
[Home]
[Reports] [Startups]
[Press Releases] [ONLINE
STORE] [site map]
